Clinical trials: Phosphorus and Calcium Disorders
X-linked Hypophosphatemia
Study of the Anti-FGF23 Antibody, Burosumab, in Adults With XLH
This is phase 3b open-label, international, multicenter study to continue to monitor the long-term safety and efficacy of burosumab in adult patients with XLH that participated in previous clinical trials with burosumab…
- Trial name
- NCT03920072
- Testing
- Burosumab
- Where
- 10 sites in France, Ireland and 2 more
- Volunteers
- 35 people
- Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
X-Linked Hypophosphataemia
A UK Multicentre, Health-Related Quality of Life Study for Children and Adolescents With XLH
This study aims to provide Health-related Quality of Life (HRQoL) data from children and adolescents with growing skeletons in the United Kingdom (UK), including those treated with burosumab or alternative XLH treatment, as part…
- Trial name
- NCT04819490
- Where
- 6 sites in United Kingdom
- Volunteers
- 32 people
- Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
Degenerative Heart Valve Disease, Heart Valve Calcification
Calcium-Phosphorus Regulation Therapy on Heart Valve Disease
The goal of this clinical trial is to learn if calcium-phosphorus regulation therapy can slow the progression of heart valve calcification in patients with degenerative heart valve disease and chronic kidney disease (CKD).
- Conditions
- Degenerative Heart Valve Disease, Heart Valve Calcification, Chronic Kidney Disease(CKD), Calcium-Phosphorus Metabolism Disorders
- Trial name
- NCT06660524
- Testing
- Sevelamer, Calcium carbonate
- Where
- China
- Volunteers
- 196 people
- Sponsor
- China National Center for Cardiovascular Diseases
Chronic Kidney Disease
Calcium and Phosphorus Balance and Calcium Kinetics in Patients With Stage 3/4 Chronic Kidney Disease
The purpose of this study is to gain a better understanding of calcium absorption and metabolism in patients with Chronic Kidney Disease (CKD) using calcium balance and kinetic methods.
- Trial name
- NCT01161407
- Testing
- 1500 mg/d elemental calcium as calcium carbonate
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Indiana University
X-linked Hypophosphatemia
X-linked Hypophosphatemia and FGF21
Fibroblast Growth Factor 23 and Fibroblast Growth Factor 21 are two endocrine Fibroblast Growth Factors, requiring Klotho as a co-factor to promote their systemic actions.
- Trial name
- XLH 21 (NCT03596554)
- Testing
- Descriptive study
- Where
- 3 sites in France
- Volunteers
- 39 people
- Sponsor
- Hospices Civils de Lyon
COVID-19 Infection, Parathyroid Gland
The Status of Parathyroid Hormone Secretion in Covid-19 Patients
COVID-19 infection causes a hypersensitive immune reaction and widespread inflammation in various organs of the body, especially through cytokines in the lungs.
- Conditions
- COVID-19 Infection, Parathyroid Gland, Parathyroid Hormone, Calcium
- Trial name
- NCT04662437
- Testing
- Venous blood was collected for biochemistry testing
- Where
- Turkey (Türkiye)
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Bezmialem Vakif University
X-linked Hypophosphatemia
Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH)
The objectives of the study are to: Identify a dose and dosing regimen of burosumab, based on safety and pharmacodynamic (PD) effect, in pediatric XLH participants Establish the safety profile of burosumab for the treatment of…
- Trial name
- NCT02163577
- Testing
- burosumab
- Where
- 9 sites in United States, France and 2 more
- Volunteers
- 52 people
- Sponsor
- Kyowa Kirin, Inc.
Premature Ovarian Failure
Levels of Selected Macroelements in Premature Ovarian Insufficiency
Aim: To evaluate plasma zinc (Zn), copper (Cu), calcium (Ca), iron (Fe), manganese (Mn), selenium (Se), strontium (Sr), aluminum (Al), antimonium (Sb), phosphorus (P), magnesium (Mg), sodium (Na), potassium (K), barium (Ba) and…
- Trial name
- POİ&MACROs (NCT04800705)
- Testing
- ultrasound assessment
- Where
- Turkey (Türkiye)
- Volunteers
- 140 people
- Sponsor
- Cengiz Gokcek Women's and Children's Hospital
Hypophosphatemic Rickets
Burosumab and 1-25 (OH) Vitamin D on Human Osteoclasts
Fibroblast growth factor 23 (FGF23) is the cornerstone of phosphate / calcium / vitamin D metabolism: it is synthesized mainly by osteocytes and acts as a Phosphating agent, inhibitor of dihydroxyvitamin D, and inhibitor of…
- Trial name
- HYPO-CLASTE (NCT04184661)
- Testing
- blood sample
- Where
- 3 sites in France
- Volunteers
- 52 people
- Sponsor
- Hospices Civils de Lyon
X-linked Hypophosphatemia, Tumor-Induced Osteomalacia
Expanded Access to Burosumab
Individual patient expanded access requests may be considered for patients who have no other treatment options
- Trial name
- NCT03775187
- Testing
- Burosumab
- Sponsor
- Kyowa Kirin Co., Ltd.
Hypophosphatemia, Hypophosphatemic Rickets
Open Label Trial Assessing Safety and Efficacy of Burosumab (KRN23), in a Patient With ENS and Hypophosphatemic Rickets
A 52 week, open label trial to assess the safety and efficacy of KRN23, an investigational antibody to FGF23, in a single pediatric patient with Epidermal Nevus Syndrome(ENS) and associated hypophosphatemic rickets A 26 weeks…
- Conditions
- Hypophosphatemia, Hypophosphatemic Rickets, Pain, Chronic
- Trial name
- NCT03581591
- Testing
- Burosumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Redwood Dermatology Sciences
X-linked Hypophosphatemia
An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia
The primary purpose of this study is to assess the safety and efficacy of repeated subcutaneous (SC) injections of KRN23 in adult subjects with X-Linked Hypophosphatemia (XLH).
- Trial name
- NCT01571596
- Testing
- KRN23
- Where
- 6 sites in United States, Canada
- Volunteers
- 23 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Hypophosphatemic Rickets, X-Linked Dominant
Effect of Cinacalcet on Parathyroid Hormone Secretion in Children and Adolescents With Hypophosphatemic Rickets
This study will measure the effect of cinacalcet (Sensipar) on parathyroid hormone (PTH) secretion in children and adolescents with hypophosphatemic rickets (XLH).
- Trial name
- NCT00195936
- Testing
- Cinacalcet
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Children's Mercy Hospital Kansas City
Hypophosphatemic Rickets, Growth Disorders
Effects of GH on Body Proportions and Final Height in X-Linked Hypophosphatemic Rickets
X-linked hypophosphatemic rickets (XLH) is characterized by rickets, disproportionate short stature, impaired renal phosphate reabsorption and vitamin D metabolism.
- Conditions
- Hypophosphatemic Rickets, Growth Disorders, Somatropin Therapy
- Trial name
- NCT00473187
- Testing
- somatropin
- Where
- Germany
- Sponsor
- University of Rostock
Preterm Labor, Parathyroid Diseases
The Association Between Parathyroid Hormone and Preterm Labor
This observational study aims to test the level of parathyroid hormone in pregnant women. The main question it aims to answer is: n Pregnant women, are the levels of serum PTH, calcium, magnesium, phosphorus \& albumin similar in…
- Trial name
- NCT05688007
- Testing
- parathyroid hormone level, serum electrolytes
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Ain Shams Maternity Hospital
Bullosa Epidermolysis, Vitamin D Deficiency
Vitamin D Status and Bone Metabolism Status in Children With Congenital Epidermolysis Bullosa
This retrospective prospective study is aimed at studying the level of vitamin D supply and identifying markers of bone tissue remodeling in order to develop approaches to the prevention of osteopenia and osteoporosis in children…
- Conditions
- Bullosa Epidermolysis, Vitamin D Deficiency, Osteoporosis, Osteopenia
- Trial name
- NCT05141838
- Testing
- Vitamin D, Oral nutritional supplement
- Where
- Russia
- Volunteers
- 110 people
- Sponsor
- National Medical Research Center for Children's Health, Russian Federation
Familial Hypophosphatemic Rickets
Calcimimetics in Hypophosphatemic Rickets
Currently, large oral doses of phosphate and 1,25(OH)2D (calcitriol) are the standard treatment of patients with familial hypophosphatemic rickets (XLH).
- Trial name
- CHR (NCT00844740)
- Testing
- Cinacalcet
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Children's Mercy Hospital Kansas City
Osteomalacia
Cinacalcet for Fibroblast Growth Factor 23 (FGF23)-Mediated Hypophosphatemia (Hypophosphatemic Rickets)
Background: Hypophosphatemia is a condition where a person has low levels of phosphorus in the blood. Low blood phosphorus can cause muscle and bone weakness (such as rickets) and teeth problems.
- Trial name
- NCT01748812
- Testing
- Osteomalacia
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
Rare Diseases, X-linked Hypophosphatemia
Burosumab in Children and Adolescents With X-linked Hypophosphatemia
In this prospective longitudinal cohort study we studied the efficacy and safety of burosumab in real-clinical practice for <13- and >13-years old children affected with X-linked hypophosphatemia.
- Trial name
- NCT04419363
- Testing
- Burosumab Injection
- Where
- France
- Volunteers
- 57 people
- Sponsor
- Bicetre Hospital
Infant, Premature, Diseases
Calcium (ca),Phosphorus( P) and 25-hydroxyvitamin D(25OHD)] in Infants Born ≤ 32 PMA Gestational Weeks (GA)
It has not yet been established the optimal dose of vit. D for preterm infants in Poland. It is not known what dose of vit. D will provide the correct concentration of vit.
- Trial name
- Ca-P (NCT03691896)
- Testing
- Cholecalciferol 400, Cholecalciferol 800, Cholecalciferol 1200
- Where
- Poland
- Volunteers
- 200 people
- Sponsor
- Centre of Postgraduate Medical Education